“The Tome” to be broken down
FDA's proposed rule on safety reporting requirements (dubbed "The Tome" for its large size) could be divided into "discrete pieces" to make it more palatable when it is finalized, Office of Pharmacoepidemiology & Statistical Science Director Paul Seligman tells Drug Information Association annual meeting. CDER Acting Director Steven Galson says the proposed rule, released in March 2003, is undergoing some "very, very serious surgical work" and the final reg will probably be something "quite different"...
You may also be interested in...
Governor Cuomo will establish two panels, one examining safety and efficacy and another considering distribution and pricing, to advise the state on how to approach use of coronavirus vaccines once one is approved.
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’